DK1102594T3 - Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin - Google Patents

Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin

Info

Publication number
DK1102594T3
DK1102594T3 DK99936674T DK99936674T DK1102594T3 DK 1102594 T3 DK1102594 T3 DK 1102594T3 DK 99936674 T DK99936674 T DK 99936674T DK 99936674 T DK99936674 T DK 99936674T DK 1102594 T3 DK1102594 T3 DK 1102594T3
Authority
DK
Denmark
Prior art keywords
sodium chloride
reduce
camptothecin derivatives
gastrointestinal toxicity
gastrointestinal
Prior art date
Application number
DK99936674T
Other languages
Danish (da)
English (en)
Inventor
Herve Toutain
Magali Guffroy
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9810043A external-priority patent/FR2782009B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1102594T3 publication Critical patent/DK1102594T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DK99936674T 1998-08-05 1999-08-03 Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin DK1102594T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12
PCT/FR1999/001916 WO2000007605A1 (fr) 1998-08-05 1999-08-03 Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite

Publications (1)

Publication Number Publication Date
DK1102594T3 true DK1102594T3 (da) 2002-08-26

Family

ID=26234482

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99936674T DK1102594T3 (da) 1998-08-05 1999-08-03 Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin

Country Status (24)

Country Link
US (1) US6476043B1 (xx)
EP (1) EP1102594B1 (xx)
JP (1) JP2002522392A (xx)
KR (1) KR20010072228A (xx)
AT (1) ATE217531T1 (xx)
AU (1) AU771195B2 (xx)
BG (1) BG64641B1 (xx)
CA (1) CA2340020A1 (xx)
CZ (1) CZ295775B6 (xx)
DE (1) DE69901506T2 (xx)
DK (1) DK1102594T3 (xx)
EA (1) EA002917B1 (xx)
EE (1) EE04264B1 (xx)
ES (1) ES2176009T3 (xx)
GE (1) GEP20043254B (xx)
HU (1) HUP0103314A3 (xx)
ID (1) ID27253A (xx)
IL (1) IL141232A0 (xx)
NO (1) NO20010454L (xx)
NZ (1) NZ509859A (xx)
PT (1) PT1102594E (xx)
SK (1) SK1732001A3 (xx)
TR (1) TR200100331T2 (xx)
WO (1) WO2000007605A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1749540B1 (en) 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
EP1714653B1 (en) * 2004-02-13 2010-11-24 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing a camptothecin
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
JP2006151950A (ja) * 2004-11-05 2006-06-15 Oto Corporation:Kk 納豆菌培養エキス含有製剤及び納豆菌培養エキスの保存方法
PL1846412T3 (pl) * 2005-02-07 2010-03-31 Fermion Oy Sposób wytwarzania 7-etylo-10-hydroksykamptotecyny
PL1928883T3 (pl) * 2005-02-08 2014-03-31 Fermion Oy Sposób otrzymywania chlorowodorku irynotekanu
US7662964B2 (en) * 2005-02-08 2010-02-16 Fermion Oy Process for producing [1,4′] bipiperidinyl-1′-carbonyl chloride or hydrochloride thereof
CA2503099A1 (en) * 2005-04-18 2006-10-18 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
JP5190958B2 (ja) 2005-07-14 2013-04-24 ウェルスタット バイオロジクス コーポレイション ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284579A (en) * 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
CA1332413C (en) * 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5225404A (en) 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
AU3684395A (en) 1994-10-06 1996-05-02 Leon T. Atlas Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
CA2340020A1 (fr) 2000-02-17
NO20010454D0 (no) 2001-01-26
BG64641B1 (bg) 2005-10-31
EP1102594A1 (fr) 2001-05-30
BG105216A (en) 2001-10-31
AU5168799A (en) 2000-02-28
JP2002522392A (ja) 2002-07-23
HUP0103314A2 (hu) 2002-01-28
PT1102594E (pt) 2002-10-31
NO20010454L (no) 2001-01-26
KR20010072228A (ko) 2001-07-31
SK1732001A3 (en) 2001-06-11
EA002917B1 (ru) 2002-10-31
CZ2001382A3 (en) 2001-05-16
CZ295775B6 (cs) 2005-11-16
EA200100214A1 (ru) 2001-08-27
ES2176009T3 (es) 2002-11-16
EE04264B1 (et) 2004-04-15
AU771195B2 (en) 2004-03-18
ATE217531T1 (de) 2002-06-15
DE69901506D1 (de) 2002-06-20
EE200100066A (et) 2002-06-17
WO2000007605A1 (fr) 2000-02-17
ID27253A (id) 2001-03-22
NZ509859A (en) 2003-09-26
HUP0103314A3 (en) 2002-07-29
EP1102594B1 (fr) 2002-05-15
DE69901506T2 (de) 2002-11-28
IL141232A0 (en) 2002-03-10
TR200100331T2 (tr) 2001-07-23
GEP20043254B (en) 2004-06-25
US6476043B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MA27040A1 (fr) Nucleosides substitues en 4'
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
MXPA03005464A (es) Agentes antivirales.
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
ME00017B (me) Derivati kamptotecina koji imaju antitumorno dejstvo
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
MXPA03011510A (es) Derivados de5-halo-triptamina usados como ligandos de receptores de serotonina 5-ht-6 y/o 5-ht-7.
DK1017675T3 (da) Stærkt lipofile camptothecinderivater
DK1102594T3 (da) Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AP9801377A0 (en) Tricyclic erythromycin derivatives.
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
DK1412332T3 (da) Quinolinderivater og anvendelse deraf som antitumormidler
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
SE0002211D0 (sv) Methods and compositions for prevention of myopia
PT1280527E (pt) Utilizacao de derivados de acriloil distamicina no tratamento de tumores associados a niveis de glutationa elevados
EE200200660A (et) Akrüloüüldistamütsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritudravimpreparaat
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
AP9801235A0 (en) Erythromycin derivatives.